ライフサイエンスコーパス: Clostridium difficile

1 fluence susceptibility to pathogens, such as Clostridium difficile.

2 re-forming pathogens, Bacillus anthracis and Clostridium difficile.

3 ation among LFAs for influenza, malaria, and Clostridium difficile.

4 and TcdB are the major virulence factors of Clostridium difficile.

5 nzyme, SrtB, is conserved between strains of Clostridium difficile.

6 of TcdB varies between different strains of Clostridium difficile.

7 tion resistance against pathogens, including Clostridium difficile.

8 creasing susceptibility to pathogens such as Clostridium difficile.

9 a, Eggerthella, and the potential pathobiont Clostridium difficile.

10 Quality control ranges for Clostridium difficile (0.12 to 1 mug/ml) and Eggerthella

11 Clostridium difficile 027/NAP1/BI is the most common C.

12 500 muM and are known to block the growth of Clostridium difficile(1), promote hepatocellular carcino

13 tracheostomy (21.6% vs 4.5%), development of Clostridium difficile (4.5% vs 1.7%), and incidence dens

14 gens detected by the FilmArray GI panel were Clostridium difficile (55.0%), Campylobacter species (20

15 nfective aetiology (112/1207 (9.2%)) such as Clostridium difficile (97/1048 (9.3%) tested) or virolog

16 Among these, Clostridium difficile, a major cause of antibiotic-induc

17 The glucosyltransferase TcdB from Clostridium difficile, a well-studied RhoA-inactivating

18 agents also increase the risk of developing Clostridium difficile (also known as Clostridioides diff

19 than 30 residents included those related to Clostridium difficile, anaerobes, Candida spp., Streptoc

20 mice datasets, investigating infection with Clostridium difficile and an immune-modulatory probiotic

21 TcdB) are produced by the bacterial pathogen Clostridium difficile and are responsible for the pathol

22 (endospores), such as those of the pathogens Clostridium difficile and Bacillus anthracis, are unique

23 outcomes of hospitalized patients tested for Clostridium difficile and determine the correlation betw

24 Herein, we establish Clostridium difficile and its enterotoxin A (TcdA) as Py

25 nzymatic activity of DisA-like proteins from Clostridium difficile and Methanocaldococcus jannaschii.

26 fections of Gram-positive bacteria including Clostridium difficile and methicillin-resistant Staphylo

27 microbiota of gnotobiotic mice infected with Clostridium difficile and the core microbiota of the sea

28 applies to the CD27L endolysin that targets Clostridium difficile and the CS74L endolysin that targe

29 ssociation of proton pump inhibitor use with Clostridium difficile and ventilator-associated pneumoni

30 aphylococcus aureus, Pseudomonas aeruginosa, Clostridium difficile, and fungal infections) in pediatr

31 rio cholerae, the hydrosulphide channel from Clostridium difficile, and the uncharacterized channel f

32 g activity in vivo against Shiga, botulinum, Clostridium difficile, anthrax, and ricin toxins.

33 a key prevention strategy for resistance and Clostridium difficile Antibiotic stewardship programs (A

34 Infections with Clostridium difficile are a health threat, yet no produc

35 Nosocomial infections with Clostridium difficile are on the rise in the Unites Stat

36 Clostridium difficile-associated diarrhea (CDAD) is comm

37 d mortality rates associated with nosocomial Clostridium difficile-associated diarrhea (CDAD), a seri

38 ting toxin B from highly virulent strains of Clostridium difficile (BI/NAP-1/027) in stool.

39 Clostridium difficile (C. difficile) incidence has tripl

40 In the intestinal pathogen Clostridium difficile, c-di-GMP inhibits flagellar motil

41 Clostridioides difficile (formerly Clostridium difficile; C difficile), the leading cause o

42 Clostridium difficile causes toxin-mediated nosocomial d

43 All samples positive for Clostridium difficile (CD) and its toxin were considered

44 lt from a polymerase chain reaction test for Clostridium difficile (CD) toxin 8 weeks after the alloc

45 In the Clostridium difficile cell wall protein family, we show

46 HAIs were pneumonia (48%), sepsis (20%), and Clostridium difficile colitis (18%).

47 transplantation (FMT) utilized for relapsing Clostridium difficile colitis successfully eradicated co

48 ated hospital length of stay, development of Clostridium difficile colitis, and total hospital cost.

49 perative pneumonia, urinary tract infection, Clostridium difficile colitis, sepsis, or death.

50 Patients with differential diagnosis (Clostridium difficile colitis, viral colitis, inflammato

51 istula, stricture/obstruction, and fulminant Clostridium difficile colitis.

52 ctobacilli in the course of her treatment of Clostridium difficile colitis.

53 ical history significant for acid reflux and Clostridium difficile colitis.

54 ng of the role of patients with asymptomatic Clostridium difficile colonization in transmission.

55 No Clostridium difficile colonization or C. difficile infec

56 Clostridioides (Clostridium) difficile colonization is common among infa

57 The diarrheal pathogen Clostridium difficile consists of at least six distinct

58 r expressing the HIV-1-derived Gag Ag or the Clostridium difficile-derived toxin B resulted in signif

59 There is no stand-alone Clostridium difficile diagnostic that can sensitively an

60 Many factors may cause diarrhoea, including Clostridium difficile, drugs (e.g. laxatives, antibiotic

61 s that are not reported at this institution (Clostridium difficile, enteroaggregative Escherichia col

62 an acquire multidrug-resistant organisms and Clostridium difficile from inadequately disinfected envi

63 eliable tools for the detection of toxigenic Clostridium difficile from unformed (liquid or soft) sto

64 Successful sequencing of the Clostridium difficile genome requires high-quality genom

65 In the past decade Clostridium difficile has become a bacterial pathogen of

66 Clostridium difficile has become one of the most common

67 Clostridium difficile has emerged as a noteworthy pathog

68 Unlike in B. subtilis, SpoIIQ of Clostridium difficile has intact LytM zinc-binding motif

69 and metagenomic shotgun sequencing (MSS) for Clostridium difficile identification in diarrhea stool s

70 , drug-product-related impurities of an anti-Clostridium difficile IgG1 mAb drug substance were profi

71 The role of Clostridium difficile in causing disease in infants is u

72 The horizontal transmission of Clostridium difficile in the hospital environment is dif

73 for treatment of recurrent infections (i.e., Clostridium difficile) in the human gut and as a general

74 Drivers of differences in Clostridium difficile incidence across acute and long-te

75 were rated >6 in all criteria: 2 measures of Clostridium difficile incidence, incidence of drug-resis

76 h daptomycin (MIC90 0.5 vs 2 mug/mL) against Clostridium difficile including NAP1 epidemic strains.

77 zole: 2), and one patient was diagnosed with Clostridium difficile infection (0 vs 1).

78 ently encountered infectious etiologies were Clostridium difficile infection (13.3% and 11.8%, respec

79 plification tests (NAATs) do not distinguish Clostridium difficile infection (CDI) and asymptomatic C

80 Isolates obtained from patients with Clostridium difficile infection (CDI) and colonization i

81 e advances in the diagnosis and treatment of Clostridium difficile infection (CDI) and prevention eff

82 s of Staphylococcus aureus bacteremia (SAB), Clostridium difficile infection (CDI) and vancomycin-res

83 Candidemia and Clostridium difficile infection (CDI) are important heal

84 es suggest that most cases of hospital-onset Clostridium difficile infection (CDI) are unrelated to o

85 methods may underestimate the true burden of Clostridium difficile infection (CDI) because they fail

86 Prevention and management of Clostridium difficile infection (CDI) can be improved by

87 Clostridium difficile infection (CDI) can cause severe d

88 Little is known about pediatric Clostridium difficile infection (CDI) epidemiology.

89 Clostridium difficile infection (CDI) following antibiot

90 Recurrent or refractory Clostridium difficile infection (CDI) has become an incr

91 dences of antibiotic-associated diarrhea and Clostridium difficile infection (CDI) has been demonstra

92 icrobiota transplantation (FMT) in recurrent Clostridium difficile infection (CDI) has been limited t

93 Patients with recurrent Clostridium difficile infection (CDI) have a >/=60% risk

94 Since 2000, the incidence and severity of Clostridium difficile infection (CDI) have increased.

95 The currently available diagnostics for Clostridium difficile infection (CDI) have major limitat

96 id suppression medication is associated with Clostridium difficile infection (CDI) in adults and is i

97 dies on risk factors for and transmission of Clostridium difficile infection (CDI) in China have been

98 ) is highly effective for treating recurrent Clostridium difficile infection (CDI) in observational s

99 e an appropriate therapeutic option for mild Clostridium difficile infection (CDI) in select patients

100 Clostridium difficile infection (CDI) is a frequent comp

101 Clostridium difficile infection (CDI) is a leading cause

102 Clostridium difficile infection (CDI) is a major burden

103 Clostridium difficile infection (CDI) is a major cause o

104 Clostridium difficile infection (CDI) is a major nosocom

105 Clostridium difficile infection (CDI) is a serious compl

106 Clostridium difficile infection (CDI) is an important ho

107 Clostridium difficile infection (CDI) is associated with

108 Clostridium difficile infection (CDI) is common after li

109 Clostridium difficile infection (CDI) is facilitated by

110 Clostridium difficile infection (CDI) is mediated by act

111 Clostridium difficile infection (CDI) is mediated by two

112 mal therapy for critically ill patients with Clostridium difficile infection (CDI) is not known.

113 f fecal microbiota transplantation (FMT) for Clostridium difficile infection (CDI) is not well-known.

114 Recurrent Clostridium difficile infection (CDI) is of particular c

115 Clostridium difficile infection (CDI) is the leading cau

116 Clostridium difficile infection (CDI) is the most common

117 Clostridium difficile infection (CDI) is the number one

118 Managing recurrent Clostridium difficile infection (CDI) presents a signifi

119 Variation in Clostridium difficile infection (CDI) rates between heal

120 rganism bloodstream infection (MDRO-BSI) and Clostridium difficile infection (CDI) rates in the 12 mo

121 This study analyzes and reports Clostridium difficile infection (CDI) rates, risk factor

122 innate immune response to the resolution of Clostridium difficile infection (CDI) remains incomplete

123 Clostridium difficile infection (CDI) represents an impo

124 Clostridium difficile infection (CDI) represents the mos

125 crobiota transplant (FMT) is recommended for Clostridium difficile infection (CDI) treatment; however

126 for the efficacy of probiotics in preventing Clostridium difficile infection (CDI), but guidelines do

127 (FT) is a promising treatment for recurrent Clostridium difficile infection (CDI), but its true effe

128 Unfortunately, the rise of Clostridium difficile infection (CDI), particularly in e

129 During treatment of Clostridium difficile infection (CDI), patterns of patho

130 Clostridium difficile infection (CDI), the most common h

131 es have evaluated risk factors for recurrent Clostridium difficile infection (CDI), the vast majority

132 ens, including acute kidney injury (AKI) and Clostridium difficile infection (CDI), were also conside

133 -Counterpoint on the laboratory diagnosis of Clostridium difficile infection (CDI).

134 rope and the United States for patients with Clostridium difficile infection (CDI).

135 e to severe disease and treatment failure in Clostridium difficile infection (CDI).

136 nts, including acute kidney injury (AKI) and Clostridium difficile infection (CDI).

137 is a highly effective therapy for recurrent Clostridium difficile infection (CDI).

138 ease states, and the prototypical example is Clostridium difficile infection (CDI).

139 an transplantation (Tx) is a risk factor for Clostridium difficile infection (CDI).

140 he gastrointestinal microbiome to facilitate Clostridium difficile infection (CDI).

141 peutic effects of dietary supplementation on Clostridium difficile infection (CDI).

142 considered important for protection against Clostridium difficile infection (CDI).

143 is a highly effective therapy for recurrent Clostridium difficile infection (CDI).

144 h care-onset health care facility-associated Clostridium difficile infection (HO-CDI) is overdiagnose

145 actam (PIP/TAZO) shortage and hospital-onset Clostridium difficile infection (HO-CDI) risk in 88 US m

146 Recurrent Clostridium difficile infection (RCDI) is associated wit

147 T) is recommended for treatment of recurrent Clostridium difficile infection (rCDI).

148 ed hospitalization, and hospitalization with Clostridium difficile infection [CDI]) were associated w

149 Clostridium difficile infection after LT was associated

150 ts it has been successfully used in cases of Clostridium difficile infection and IBD, although contro

151 We also assessed rates of Clostridium difficile infection and potential allergic r

152 ctors affecting a person's susceptibility to Clostridium difficile infection are well-understood, lit

153 s is not observed in subjects with recurrent Clostridium difficile infection but is observed in the s

154 Clostridium difficile infection causes severe complicati

155 The gut microbiota in recurrent Clostridium difficile infection had lower density and re

156 The incidence of Clostridium difficile infection has increased among chil

157 Clostridium difficile infection has increased in inciden

158 Clostridium difficile infection in LT recipients was ass

159 We compared rates of recurrent Clostridium difficile infection in patients receiving or

160 The detection and diagnosis of Clostridium difficile infection in pediatric populations

161 The magnitude and scope of Clostridium difficile infection in the United States con

162 Colitis caused by Clostridium difficile infection is a growing cause of hu

163 Clostridium difficile infection is a growing problem in

164 Targeting Clostridium difficile infection is challenging because t

165 Their use as probiotics for prevention of Clostridium difficile infection is prevalent among consu

166 Clostridium difficile infection is the leading cause of

167 Clostridium difficile infection is the leading cause of

168 Clostridium difficile infection is the most common healt

169 Clostridium difficile infection occurred in 27 (14%) of

170 Clostridium difficile infection often occurred soon afte

171 reports found addressed the use of FMTs for Clostridium difficile infection or inflammatory bowel di

172 dmission rates, central venous catheter use, Clostridium difficile infection rates, and hospital leng

173 8, P = 0.04, I = 36%), with no difference in Clostridium difficile infection rates.

174 e-level association test of the reduction in Clostridium difficile infection recurrence in patients t

175 Whereas many antibiotics increase risk of Clostridium difficile infection through dysbiosis, epide

176 cohort of 109 subjects treated for recurrent Clostridium difficile infection with fecal microbiota tr

177 t serious cephalosporin-associated ADRs were Clostridium difficile infection within 90 days (0.91%),

178 ated charges for inflammatory bowel disease, Clostridium difficile infection, and chronic liver disea

179 with outcomes (antibiotic-days, incidence of Clostridium difficile infection, and in-hospital mortali

180 numbers of Staphylococcus aureus bacteremia, Clostridium difficile infection, and vancomycin-resistan

181 viously used to cure patients with recurrent Clostridium difficile infection, could also protect agai

182 for the same infection, acute kidney injury, Clostridium difficile infection, or drug-related adverse

183 py, and frequency of complications including Clostridium difficile infection, readmission, and all-ca

184 ation (FMT) is effective in the treatment of Clostridium difficile infection, where efficacy correlat

185 acious and inexpensive therapy for recurrent Clostridium difficile infection, yet its safety is thoug

186 and fidaxomicin are therapies of choice for Clostridium difficile infection.

187 ns about promoting antibiotic resistance and Clostridium difficile infection.

188 mycin antibiotic treatment and opportunistic Clostridium difficile infection.

189 contributes to the pathology observed during Clostridium difficile infection.

190 rectal procedures without increased risk of Clostridium difficile infection.

191 a transplantation for treatment of recurrent Clostridium difficile infection.

192 idity, development of ileus, reoperation and Clostridium difficile infection.

193 xolidinone antibiotic developed for treating Clostridium difficile infection.

194 nsecutive, evaluable patients with recurrent Clostridium difficile infection.

195 or-associated complication or pneumonia, and Clostridium difficile infection; minor outcomes included

196 trum antibiotic approved for Clostridioides (Clostridium) difficile infection (CDI) in adults, is ass

197 Clostridioides (formerly Clostridium) difficile infection (CDI) is associated wit

198 is and treatment of Clostridioides (formerly Clostridium) difficile infection (CDI).

199 Community-onset Clostridium difficile infections (CDI) are increasingly

200 ic, is an investigational drug indicated for Clostridium difficile infections (CDI).

201 BACKGROUND & AIMS: Studies of Clostridium difficile infections (CDIs) among individual

202 Clostridium difficile infections (CDIs) are a growing he

203 d dysbiosis is a key predisposing factor for Clostridium difficile infections (CDIs), which cause int

204 al microbiota transplantation to face severe Clostridium difficile infections and to perform decoloni

205 n-resistant Staphylococcus aureus (MRSA) and Clostridium difficile infections declined across the UK

206 biotic-based strategies for the treatment of Clostridium difficile infections disrupt indigenous micr

207 The prevalence of Clostridium difficile infections has increased due to th

208 The control of Clostridium difficile infections is an international cli

209 as oral non-systemic antibacterial drugs for Clostridium difficile infections were active against pat

210 han 9000 nosocomial infections, 1000 to 5000 Clostridium difficile infections, and 2 to 6 cases of an

211 den of antimicrobial-resistant organisms and Clostridium difficile infections, halting unnecessary an

212 , ventilator-associated pneumonia (VAP), and Clostridium difficile infections.

213 riptions) ADRs, with Clostridiodes (formerly Clostridium) difficile infections pivotal to its ADR pro

214 Clostridium difficile is a clinically significant pathog

215 Clostridium difficile is a gastrointestinal pathogen but

216 Clostridium difficile is a Gram-positive bacterium with

217 The spore-forming bacterial pathogen Clostridium difficile is a leading cause of health-care-

218 Clostridium difficile is a major nosocomial pathogen tha

219 Clostridium difficile is a major, life-threatening hospi

220 jor cause of antibiotic-associated diarrhea, Clostridium difficile is a serious problem in health car

221 Clostridium difficile is a significant concern as a noso

222 Clostridium difficile is a significant pathogen in healt

223 orming, healthcare-associated enteropathogen Clostridium difficile is actively undergoing speciation.

224 Clostridium difficile is an anaerobic and spore-forming

225 Clostridium difficile is an anaerobic pathogen that form

226 Clostridium difficile is an important pathogen causing s

227 tion with the opportunistic enteric pathogen Clostridium difficile is an increasingly common clinical

228 Clostridium difficile is an opportunistic pathogen that

229 Clostridium difficile is currently the leading cause of

230 ecal toxin negative (FT-) in transmission of Clostridium difficile is currently unknown.

231 The pathogenicity of Clostridium difficile is linked to its ability to produc

232 Clostridium difficile is one of the most common nosocomi

233 Clostridium difficile is the cause of antibiotics-associ

234 The spore-forming gut bacterium Clostridium difficile is the leading cause of antibiotic

235 Clostridium difficile is the leading cause of hospital-a

236 Clostridium difficile is the leading cause of infectious

237 Clostridium difficile is the most common cause of health

238 Clostridium difficile is the most common hospital acquir

239 Clostridium difficile is the most commonly identified pa

240 Clostridium difficile is the most commonly reported noso

241 Clostridium difficile is the most frequently identified

242 Clostridium difficile is the most important enteropathog

243 Clostridium difficile is the principal cause of nosocomi

244 Although Clostridium difficile is widely considered an antibiotic

245 Clostridium difficile is widely publicised as a problem

246 Clostridioides (formerly Clostridium) difficile is a Gram-positive, spore-forming

247 Clostridioides (formerly Clostridium) difficile is a leading cause of healthcare-

248 Clostridioides (formerly known as Clostridium) difficile is the leading cause of hospital-

249 Clostridioides (formerly Clostridium) difficile is the most common cause of hospi

250 ts to the health service and predisposing to Clostridium difficile, methicillin-resistant Staphylococ

251 ntamination, colonization, or infection with Clostridium difficile, methicillin-resistant Staphylococ

252 rienced a major outbreak associated with the Clostridium difficile NAP1/027/BI strain.

253 Diarrhoea positive for Clostridium difficile occurred in two patients (<1%) in

254 ed in colonic neurons of human patients with Clostridium difficile or ulcerative colitis.

255 No effect was observed on incidence of Clostridium difficile (OR 1.02, 95% CI 0.34-3.01), and m

256 on of spores is critical for the survival of Clostridium difficile outside the host gastrointestinal

257 nhancing probiotic bacteria activity against Clostridium difficile pathogenesis in vivo.

258 tem cell regeneration and, more recently, in Clostridium difficile pathogenesis.

259 Clostridium difficile PCR ribotype 265 (toxin A negative

260 orders for ovum and parasite (O&P) exams and Clostridium difficile PCR.

261 Clostridium difficile (Peptoclostridium difficile) is a

262 ACKGROUND & AIMS: Nosocomial infections with Clostridium difficile present a considerable problem des

263 w that toxins A or B of the enteric pathogen Clostridium difficile recapitulate the salient features

264 The major global pathogen Clostridium difficile (recently renamed Clostridioides d

265 Clostridium difficile remains the leading cause of nosoc

266 pansion of several potential pathogens (e.g. Clostridium difficile, Salmonella, and Escherichia coli)

267 ansplantation led to resolution of recurrent Clostridium difficile, significantly decreased recurrent

268 obiota, which consequently enables toxigenic Clostridium difficile species to proliferate and cause i

269 hotspots associated with mobile elements in Clostridium difficile ST6 and a previously undescribed 3

270 infections (HAIs), including those caused by Clostridium difficile, Staphylococcus aureus, Pseudomona

271 Clostridium difficile strain BI/NAP1/027 is associated w

272 Clostridium difficile strains within the hypervirulent c

273 Hypervirulent Clostridium difficile strains, which are associated with

274 xin (CTB5) and a subfragment of toxin A from Clostridium difficile (TcdA-A2).

275 Clostridium difficile TcdB (2366 amino acid residues) is

276 metalloprotease from the bacterial pathogen Clostridium difficile that cleaves two endogenous adhesi

277 TcdB is one of the key virulence factors of Clostridium difficile that is responsible for causing se

278 n that we identified from the human pathogen Clostridium difficile The crystal structure shows that t

279 Clostridium difficile, the causal agent of antibiotic-as

280 Unlike other bacteria, Clostridium difficile, the major human pathogen responsi

281 inococcus obeum, Salmonella typhimurium, and Clostridium difficile) to quantify, expand, and characte

282 Clostridium difficile toxin A (TcdA) is a major exotoxin

283 Clostridium difficile toxin B (TcdB) is a critical virul

284 or Pyrin inflammasomes by nigericin (NG) or Clostridium difficile toxin B (TcdB), respectively.

285 We have shown previously that Clostridium difficile toxin B (ToxB), an inhibitor of Rh

286 Clostridium difficile toxin was subsequently detected in

287 ly from stool specimens: Campylobacter spp., Clostridium difficile (toxin A/B), Plesiomonas shigelloi

288 response to Rho-modifying toxins, including Clostridium difficile toxins A and B.

289 acid amplification test for the detection of Clostridium difficile toxins in stool specimens, with th

290 ve and quantitative methods for detection of Clostridium difficile toxins provide new tools for diagn

291 r concentrations of Clostridioides (formerly Clostridium) difficile toxins A and/or B in the stool of

292 us antibodies (eAbs) against Clostridioides (Clostridium) difficile toxins may protect against recurr

293 ty, produce the actin-ADP ribosylating toxin Clostridium difficile transferase (CDT).

294 CDT (Clostridium difficile transferase) is a binary, actin AD

295 y additionally produce the binary CDT toxin (Clostridium difficile transferase) that ADP-ribosylates

296 Accurate tracking of Clostridium difficile transmission within healthcare set

297 cy, or benign disease (diverticular disease, Clostridium difficile) undergoing major abdominal surger

298 ared to those of mapping-based approaches in Clostridium difficile, using repeated sequencing of the

299 his setting, such as Cryptosporidiumspp. and Clostridium difficile, were detected with the GPP.

300 ient stools, it detected the toxin B gene of Clostridium difficile with 95% sensitivity and 95% speci